A Randomized, Open Label Study to Compare the Complete Pathological Response Rate Achieved With 4 Combinations of Herceptin, Docetaxel and Pertuzumab in Patients With Locally Advanced, Inflammatory or Early Stage HER2 Positive Breast Cancer

Trial Profile

A Randomized, Open Label Study to Compare the Complete Pathological Response Rate Achieved With 4 Combinations of Herceptin, Docetaxel and Pertuzumab in Patients With Locally Advanced, Inflammatory or Early Stage HER2 Positive Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Pertuzumab (Primary) ; Docetaxel; Trastuzumab
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms NEOSPHERE
  • Sponsors Roche
  • Most Recent Events

    • 05 Jan 2017 Results of data from the safety populations of three trials (NEOSPHERE, CLEOPATRA and TRYPHAENA) published in the Annals of Oncology
    • 07 Jun 2016 Results assessing the modulation of tumor lymphocyte infiltration (TIL) and prognosis presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 11 May 2016 5-year results published in the Lancet Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top